Ambrisentan for Treatment of Portopulmonary Hypertension

Summary

Portopulmonary hypertension denotes pulmonary hypertension complicating portal hypertension and is present in approximately 5% of cirrhotic patients. Treatment options include prostanoids, sildenafil, and the endothelin-receptor antagonists, bosentan and ambrisentan. This study investigates the safety and efficacy of ambrisentan in portopulmonary hypertension.

Timeline

Start

2012-07

Primary completion

2016-04

Completion

2016-06

Drugs

Indications